These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19617465)

  • 41. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
    Kristensen LE; Gülfe A; Saxne T; Geborek P
    Ann Rheum Dis; 2008 Mar; 67(3):364-9. PubMed ID: 17644547
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of methotrexate and tumor necrosis factor inhibitors in Japanese patients with active psoriatic arthritis.
    Mori Y; Kuwahara Y; Chiba S; Itoi E
    Mod Rheumatol; 2015 May; 25(3):431-4. PubMed ID: 25295919
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.
    Breedveld F; Agarwal S; Yin M; Ren S; Li NF; Shaw TM; Davies BE
    J Clin Pharmacol; 2007 Sep; 47(9):1119-28. PubMed ID: 17766699
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics and safety of golimumab in healthy Chinese subjects following a single subcutaneous administration in a randomized phase I trial.
    Zhuang Y; Lyn S; Lv Y; Xu Z; Bouman-Thio E; Masterson T; Ford JA; Keen M; Petty KJ; Davis HM; Zhou H
    Clin Drug Investig; 2013 Nov; 33(11):795-800. PubMed ID: 23975656
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab.
    Scrivo R; Giardino AM; Salvarani C; Foti R; Afeltra A; Viapiana O; Giacomelli R; Salaffi F; Galeazzi M; Ramonda R; Ciccia F; Valesini G; Iannone F;
    Clin Exp Rheumatol; 2020; 38(1):107-114. PubMed ID: 31287400
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis.
    Dreesen E; Kantasiripitak W; Detrez I; Stefanović S; Vermeire S; Ferrante M; Bouillon T; Drobne D; Gils A
    Inflamm Bowel Dis; 2020 Mar; 26(4):570-580. PubMed ID: 31372650
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
    Suleiman AA; Khatri A; Minocha M; Othman AA
    Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis.
    Fasanmade AA; Adedokun OJ; Ford J; Hernandez D; Johanns J; Hu C; Davis HM; Zhou H
    Eur J Clin Pharmacol; 2009 Dec; 65(12):1211-28. PubMed ID: 19756557
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
.
    Xie R; Deng C; Wang Q; Kanik KS; Nicholas T; Menon S
    Int J Clin Pharmacol Ther; 2019 Sep; 57(9):464-473. PubMed ID: 31319908
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects.
    Ling J; Lyn S; Xu Z; Achira M; Bouman-Thio E; Shishido A; Ford J; Shankar G; Wagner C; Kim KT; Davis HM; Zhou H
    J Clin Pharmacol; 2010 Jul; 50(7):792-802. PubMed ID: 20133508
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population pharmacokinetic evaluation of a fully human IgG monoclonal antibody in patients with inflammatory diseases.
    Tabrizi M; Wang B; Lu H; Huang S; Bell G; Schwab G; Roskos L
    Inflamm Allergy Drug Targets; 2010 Sep; 9(4):229-37. PubMed ID: 20860546
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug-Drug Interactions.
    Shao J; Vetter M; Vermeulen A; Feagan BG; Sands BE; Panés J; Xu Z
    Clin Pharmacol Ther; 2024 Jun; 115(6):1418-1427. PubMed ID: 38488354
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis.
    Tran L; Yao Z; Xu Z; Vermeulen A
    Br J Clin Pharmacol; 2022 Oct; 88(10):4481-4493. PubMed ID: 35470450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis.
    Xu C; Su Y; Paccaly A; Kanamaluru V
    Clin Pharmacokinet; 2019 Nov; 58(11):1455-1467. PubMed ID: 31055792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population Pharmacokinetics and Exposure-Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis.
    Thakre N; D'Cunha R; Goebel A; Liu W; Pang Y; Suleiman AA
    Rheumatol Ther; 2022 Dec; 9(6):1587-1603. PubMed ID: 36178584
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Population Pharmacokinetics of Intravenous Methotrexate in Patients with Hematological Malignancies: Utilization of Routine Clinical Monitoring Parameters.
    Nader A; Zahran N; Alshammaa A; Altaweel H; Kassem N; Wilby KJ
    Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):221-228. PubMed ID: 27059845
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis.
    Ng CM; Lum BL; Gimenez V; Kelsey S; Allison D
    Pharm Res; 2006 Jun; 23(6):1275-84. PubMed ID: 16715358
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis.
    Chakraborty A; Van LM; Skerjanec A; Floch D; Klein UR; Krammer G; Sunkara G; Howard D
    J Clin Pharmacol; 2013 Dec; 53(12):1240-51. PubMed ID: 24122883
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Doubling golimumab doses did not improve skin disease in two obese patients with psoriatic arthritis.
    Bonifati C; Lora V; Graceffa D
    G Ital Dermatol Venereol; 2017 Dec; 152(6):670-672. PubMed ID: 29050449
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.